Journal
COLLOIDS AND SURFACES B-BIOINTERFACES
Volume 145, Issue -, Pages 8-13Publisher
ELSEVIER
DOI: 10.1016/j.colsurfb.2016.04.041
Keywords
Immuno nanoparticles; Alzheimer's disease; Blood brain-barrier; Antibodies; Drug delivery systems; Therapeutic peptides
Funding
- FCT- Fundacao para a Ciencia e a Tecnologia
- FEDER [UID/EQU/00511/2013-LEPABE, NORTE-07-0124-FEDER-000025-RL2_EnvironmentHealth]
- FCT/MEC
- FEDER funds through COMPETE
- Programa Operacional do Norte [ON2]
- FCT
- [FEUP-TRANSCAN/0001/2012]
- Fundação para a Ciência e a Tecnologia [TRANSCAN/0001/2012] Funding Source: FCT
Ask authors/readers for more resources
During the last few decades, relevant efforts have been reported to design nanocarriers for drug transport through the blood brain barrier (BBB). New drugs, such as peptide iA beta(5), capable to inhibit the aggregates associated with Alzheimeris disease (AD) are being tested but the most frequent drawback is to reach the brain in the desired concentrations due to the low BBB permeability-surface area. Our approach, as a proof of concept to improve drug transport through the BBB, is based on poly(lactic-co-glycolic acid) (PLGA) nanoparticles with surface functionalized with anti-transferrin receptor monoclonal antibody (OX26) and anti-A beta (DE2B4) to deliver encapsulated iA beta(5) into the brain. Porcine brain capillary endothelial cells (PBCECs) were used as a BBB model to evaluate the system efficacy and toxicity. The uptake of immune nanoparticles with a controlled delivery of the peptide iA beta(5) was substantially increased compared to the nanoparticles (NPs) without monoclonal antibody functionalization. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available